MEDICE Road Show Presentation MAY 2022



«key info»

ISSUER	MEDICA S.P.A.
LISTING MARKET / SEGMENT	ITALIAN STOCK EXCHANGE, EURONEXT GROWTH MILAN (PREVIOUSLY AIM ITALIA)

PLACEMENT PRICE	EUR 27.00 PER SHARE
% FREE FLOAT	20.07%
Lock-ups	 Issuer: 360 days from the listing Pelmo87 Srl (71,89% Luciano Fecondini and 28,11% Andrea Bocchi): 18 months from the listing





Top Management – Speakers



LUCIANO

FOUNDER, CHAIRMAN & CEO

- FOUNDED MEDICA IN 1985 AS AN R&D LAB
- PREVIOUSLY, HE WORKED AS CONSULTANT FOR BIOMED MNOS IN USA, THEN AS HEAD OF GLOBAL R&D AT AMICON (MASSACHUSETTS)
- GRADUATED IN CHEMICAL ENGINEERING IN 1972

Marco Fecondini



CHIEF SALES & MARKETING OFFICER

- Joined Medica in 2011
- In Medica he covered roles of increasing responsibilities across several functions
- PhD in Agricultural Sciences
 - Graduated in Agricultural Sciences

Letizia Bocchi



CHIEF IP OFFICER & HEAD OF LABORATORY

- Joined Medica in 2010
- 5yrs as Research Fellow
 at University of Modena
 & Reggio Emilia
- PhD in Biochemistry, Molecular Biology and Biotechnology
- GRADUATED IN BIOTECHNOLOGY

GIOVANNI Plasmati




IR & CHIEF FINANCIAL OFFICER

- O JOINED MEDICA IN 2021
- 15yrs as Auditor for PwC up to Senior Manager role
- MSC IN FINANCE AND CONTROL
- Graduated in Economics
 and Business
 Administration

MEDICA

INTRODUCTION TO MEDICA GROUP



MEDICA

Global solution provider for healthcare players

BIOMED AND MED-TECH R&D POWERHOUSE

IN MEMBRANES AND ELECTROMEDICAL DEVICES

LEVERAGING ON UNIQUE AND SECRET ON-THE-SHELF KNOW-HOW

ACROSS THE ENTIRE VALUE-CHAIN

OFFERING A FULL RANGE OF TURNKEY 360° READY-TO-MARKET AND MISSION CRITICAL SOLUTIONS FOR THE BLOOD AND WATER TREATMENT MARKETS

SUPPLYING INNOVATIVE AND POTENTIALLY DISRUPTIVE PRODUCTS

IN MORE THAN 60 COUNTRIES

SCALABLE TO COUNTLESS

MARKETS AND APPLICATIONS

Leading Pocket-Size Italian Multinational MedTech

KEY FACTS	Revenues Breakdown ⁽²⁾		
~75% OF REVENUES OUTSIDE ITALY	43%	Medical Disposables ⁽¹⁾	
• ~20% of FTEs in R&D and Quality	27%	Custom and Standard Assembly Line	
		WATER PURIFICATION	
19	8%		
PATENT FAMILIES			
OF WHICH 12 GRANTED	10%		
7 PENDING	4%	Oxygen Humidifier	
New products in pipeline Already CE Marked	3%	URODYNAMIC, GASTROENTEROLOGY, ONCOLOGY	




Source: Management, group consolidated financial statements

MEDICA

Notes: (1) Includes tubing sets, blood filters and ultra-filters; (2) remaining 5% is related to other minor activities, in particular R&D consultancy, technical assistance and sale of spare parts


Sound Growth & Outstanding Profitability



MEDICA

Successful Pocket-size Multinational Italian Champion

MEDICA




MEDICA'S FLEXIBILITY AND DISTINCTIVELY INTEGRATED KNOW-HOW ALLOWS TO ENTER NEW NICHES WORLDWIDE PUSHING ITS BRANDED PRODUCTS

MEDICA Sources: M

INVESTMENT HIGHLIGHTS







MediSulfone* UF hollow fiber section. SEM image at 400x

MediSulfone* is a registered trademark of Medica S.p.A.






Versatle"-PES hollow fiber section. SEM Image at 300x.

Oversatle"-PES Is a trademark of Medica S.p.A


Medica is Ready to Scale Up Unique Technology Platforms



Source: Management




Diversified Among Structurally Growing End-Markets



Source: Management accounts

All-Around, Diversified and Highly Synergic Product Offering




SUCCESSFUL PRODUCT EXTENSION TRACK-RECORD IN DIFFERENT NICHES, THANKS TO BOTH HARDWARE AND SOFTWARE TECHNOLOGY PLATFORMS

Source: Management

MEDICA

Exposure to Multiple Structurally Growing End-markets




ON-TOP OPPORTUNITY: "AT-HOME" RENAL CARE MANAGEMENT MARKET (11.4 \$B IN 2020A), WITH 9% 2020A-2025E CAGR

MEDICF

Sources: 1) Frost & Sullivan - Transformative Technology, Policy & Reimbursement Trends Driving Changes in Kidney Care Solutions, Global, 2020-2025; 2) Fresenius Annual Review 2020; 3) <u>https://www.reuters.com/business/healthcare-pharmaceuticals/diabetes-surges-among-american-youth-study-shows-2021-08-24/</u>

Exposure to Multiple Structurally Growing End-markets




GROWING AWARENESS ON ENVIRONMENTAL COST OF BOTTLED WATER CARB



ACCORDING TO UN, WORLD POPULATION WILL PASS 8BN IN THE NEXT 5 YEARS AND 2/3 WILL LIVE IN WATER-STRESSED CONDITIONS BY 2025

SIMILARLY, THE IMPLEMENTATION OF POINT-OF-ENTRY AND POINT-OF-USE FILTER SYSTEMS TO ELIMINATE PATHOGENS HAS LED TO THE PROLIFERATION OF THE MARKET, ALSO BEING THE MOST VIABLE SOLUTION IN EMERGING COUNTRIES



HUGE OPPORTUNITY FOR MEDICA TO LEVERAGE ITS TECHNOLOGY/PRODUCT PERFORMANCE CLAIMS

MEDICA

4

Fully Integrated Business Model, Unique in the MedTech Space

MEDICA

 Secret production know-how of fiber extrusion up to filter membranes assembly Few large global players able to extrude membrane hollow fibers, mainly for chronic
 ABILITY TO PRODUCE HIGHLY TAILORED MEMBRANES TO FILTER DIFFERENT SELECTED COMPONENTS FLEXIBILITY TO DEVELOP NEW TREATMENTS IN MULTIPLE MARKET NICHES
 Dialysis filters with 14 thousands fibers in parallel Ability to assembly filters of any size, from small neonatal use, to large industrial filters
 Continuous features innovation thanks to sensors and software internal expertise "Razors" allowing to continuously sell disposable "blades"










 STANDARD MACHINES FOR PROCESS OPTIMIZATION, THANKS TO THE TRANSVERSAL KNOWLEDGE ENTIRE THE VALUE-CHAIN




ENTIRE CUSTOM ASSEMBLY LINES FULLY AUTOMATED, ENSURING HIGH PRODUCTIVITY AND CONTROL

INTEGRATION IS A STRONG COMPETITIVE ADVANTAGE IN TERMS OF R&D EFFICACY AND SUPERIOR TIME-TO-MARKET

MEDICA

Source: Management

Fully Integrated Business Model, Unique in the MedTech Space



€M

Source: Management Accounts

MEDICA

Unparalleled R&D Capabilities Fueling a Rich Product Pipeline



MEMBRANES' KNOW-HOW LEADS TO HARD-TO-IMAGINE APPLICATIONS ACROSS SEVERAL MARKETS

- MEDICA DEVELOPED 9 DIFFERENT TYPES OF MEMBRANES:
 - ULTRAFILTRATION (1995)
 - HEMOFILTRATION (1995)
 - OXYGEN HUMIDIFICATION (2008)
 - MICROFILTRATION (2017)
 - PLASMAPHERESIS (2017)
 - DIALYISIS (2018)
 - PLASMA FRACTIONATION (2019)
 - LARGE-SIZE SPECIAL MEMBRANES FOR ENCAPSULATED CELLULAR THERAPY & AIR FILTRATION (2020)
 - GRAPHENE ENRICHED ULTRAFILTRATION AND MICROFILTRATION (ONGOING)

Active (Electro) Medical Devices AferSmart HOMHEMO DIASMART Image: Constraint of the state of the

- RESEARCH AREAS: (I) BOARD DESIGN (II) PROGRAMMING AND DESIGN OF SOFTWARE AND FIRMWARE, (III) TESTING AND VALIDATION, (IV) MECHANICS DESIGN OF INDUSTRIAL SYSTEMS & MACHINES
- CONSOLIDATED PARTNERSHIP WITH MISTER SMART INNOVATION AND CNR (ITALY'S NATIONAL RESEARCH COUNCIL) ALLOWING TECH-TRANSFER AND ACCESS TO HIGHLY SOPHISTICATED LAB INSTRUMENTS
- **FLAGSHIP PROJECTS** ARE RELATED TO THE DEVELOPMENT OF **SENSORS**

MANIACAL CALIBRATION IN TERMS OF FIBER DIMENSION AND POROSITY DETERMINING DISPOSABLES PERFORMANCE



Source: Management

17

S

Unparalleled R&D Capabilities Fueling a Rich Product Pipeline


MEMBRANES RESEARCH CONTINUOUSLY OPENS UP NEW FIELDS OF APPLICATIONS

NEUROTECH COMMITTED RESEARCH

NEW MEMBRANE FOR CELL ENCAPSULATION THERAPY


PROJECT COMMISSIONED BY US COMPANY NEUROTECH MEDICA FIBER IS USED AS THE POROUS SCAFFOLD FOR CELL ENCAPSULATION

CLINICAL TRIAL STARTING IN Q2.2021 MEDICA SUPPLY TO NEUROTECH STARTING IN 2021



MEDICA


ENCAPSULATED HUMAN CELLS GENETICALLY MODIFIED TO SECRETE THERAPEUTIC DOSES OF CILIARY NEUROTROPHIC FACTOR (CNTF) INTO THE BACK OF THE EYE FOR THE TREATMENT OF **RETINAL DEGENERATIVE DISEASES**



Source: Management

White Space in Water Leveraging Internal, Existing Know-How





- **HIGHLY SYNERGIC** WITH OTHER BUSINESS UNITS BOTH IN R&D AND **OPERATIONS**
- **DSU** («DUAL STAGE ULTRAFILTER) **PROPRIETARY TECHNOLOGY** GUARANTEES ABSOLUTE BEST-IN-CLASS MICROBIOLOGICAL AND **OPERATIONAL SAFETY**
- MEDICA'S INVESTING IN R&D TARGETING NEW APPLICATION OF ITS **OWN FIBER SPINNING TECHNOLOGY**

SUCCESSFUL EXPANSION INTO WATER PURIFICATION, WITHOUT ACTIVE MARKETING EFFORTS, PROVES THE SCALABILITY OF TECHNOLOGY


Source: Management



Prestigious projects funded from UE about "water" challenges

REMEMBRANCE

- GIVE PLASTIC WASTES FROM THE PRODUCTION OF HOLLOW-FIBER MEMBRANES A SECOND LIFE.
- MAIN OBJECTIVE IS THE PRODUCTION AND COMMERCIALIZATION OF SAFE AND INNOVATIVE GRANULES AND CARTRIDGES FOR DRINKING WATER PURIFICATION FROM PFASS STARTING FROM THE RECYCLE OF HIGH-VALUE INDUSTRIAL WASTE DERIVING FROM HOLLOW FIBERS MEMBRANE (HFM) FILTERS PRODUCTION.
- FUNDING OF 55% OF THE PROJECT FROM UE, STARTED SEPT. 2021, END MARCH 2025. MEDICA IS THE COORDINATING BENEFICIARY.












POTENTIALLY DISRUPRIVE GRAPHENE TECHNOLOGY







- SAMPLES OF GRAPHENE FILTERS DEVELOPED IN 2021 AND LAUNCHED AT AQUATECH EXHIBITION IN AMSTERDAM (NOV. 2021).
- TRIALS ONGOING AT CUSTOMERS' FACILITIES
- CERTIFICATION ONGOING





2021 Year Results – comparison with Analyst Research


	Medica Group FY2021	Intesa Research 20 Jan 2022	CFOSIM Research 20 Jan 2022
Revenues	43,8	43,8	43,7
Ebitda	9,9	9,3	9,4
Ebitda Adjusted	10,0 *	9,4	
Ebit	5,8	5,2	5,2
Ebit Adjusted	5,9 *	5,2	
Net Income	5,0	4,2	4,1
Net debt (net Cash)	(10,8)	(9,3)	(10,8)


* The difference applied by the Company to the Ebitda adjusted and Ebit adjusted parameters is related to the accounting of listing costs, according to the current accounting standards, which were accounted in service cost for Euro 0,1 million and capitalized for Euro 1,2 million (and amortized in 5 years from November 2021 to November 2026)


Source: Management elaboration on Group consolidated financial statements and Management Accounts



Steep Revenues Growth with Substantial Profitability








Source: Management elaboration on Group consolidated financial statements and Management Accounts



Efficient Business Model & Attractive Cash Generation Profile




MEDICA

1. Trade receivables are represented net of allowances

2. They do not include Trade payables beyond 12m as not associated to current operations and 1,4m advance for a capitalized R&D project Source: Management elaboration on consolidated financial statements

Efficient Business Model: Constant CapEx Sufficient for Growth




- Medica's CapEx are mainly expansionary to support growth, and in any case well funded by cash flow from operations
- Capitalized share of R&D refers to Development projects only, and only for clearly related live expenses (e.g. Dossier Development, prototyping, fullydedicated personnel etc.)
 - Basic Research and Early Development costs are expensed in the Income Statement (1.7 €M in 2021, vs 0.6 €M capitalized)
- SarMed and Medica Mediterranée fast volumes increase requires investments in new production lines (e.g. fiber spinning, dialyzers...) to support growth, yet the repayment period for the investment is totally acceptable within a couple of years

Source: Management elaboration on Group consolidated financial statements



FY 2020 - FY 2021 Net Financial Position Bridge



Source: Management elaboration on Group consolidated financial statements and Management Accounts




noop consolidated infancial statements and management Accounts

FUTURE STRATEGY AND IPO RATIONALE





Medica Medium Term Organic Growth Strategy



Sources: Management, group financial statements

MEDICA

M&A Strategy – Boost Sales & Product Portfolio


Well-IDENTIFIED M&A TARGETS ACROSS EUROPE AND AMERICAS

TARGET	SECTOR	COUNTRY	GEOGRAPHIC PRESENCE	SYNERGIES
Α	Medical Device distribution		Italy	Distribution
В	Medical Device distribution		Germany	Distribution
С	Medical solution bags manufacturing		Colombia	Product portfolio
D	Sensors – Active Medical Devices		Europe - USA	Manufacturing and R&D
E	Water filters manufacturing and Sales & Marketing		Europe	Medica Water Portfolio, increasing distribution network reach




Source: Management






Well and Responsibly Managed – A Strong ESG Profile







MEDICA





PIONEER INTRODUCTION IN 2020 OF MEAL VOUCHERS FOR TUNISIA PLANT WORKERS, IN ORDER TO SUSTAIN FAMILY'S ECONOMY DUE TO FOOD COMMODITIES PRICE INCREASE AND DEVALUING CURRENCY; FREE BUS SERVICE FOR NIGHT SHIFTS




APPLICATION OF EU REGULATION 2016/679 (GDPR) TO THE ITALIAN COMPANIES OF THE MEDICA GROUP THAT ARE COMPLIANT WITH A STRUCTURED PRIVACY MODEL FOR EACH COMPANY

ADOPTION OF THE ORGANIZATION AND MANAGEMENT CONTROL MODELS PURSUANT TO LEG. DECREE 231/01 AND ESTABLISHMENT OF THE SUPERVISORY BODY, AS WELL AS ETHICAL CODE



Source: Management

35+ Years Pioneering Membrane & Medical Equipment Innovation



MEDICA SHOWED GREAT RESILIENCE AFTER GLOBAL FINANCIAL CRISIS AND THE 2012 EARTHQUAKES, AND IS NOW IN THE SWEET SPOT FOR A SUCCESSFUL LISTING TO ACCELERATING GROWTH FURTHER, EXPLOITING CLEAR ORGANIC AND M&A OPPORTUNITIES

Source: Management

MEDICA

THF – Recent Highly Synergic Acquisition, for a Reasonable Price







"LUNGS" AND BAGS MANUFACTURING FOR MEDICAL USE


COMPLETING TECNOIDEAL PRODUCT AND TECH PORTFOLIO, WHILE APPORTING A NEW CASH-RICH ANCILLARY BUSINESS



Source: Management

32

Group Structure – Consolidated Entities




33

MEDICA

Sources: Management, group financial statements Note: (1) 7.89% held through Tecnoideal, 92.11% through Medica

Inter-Group Model



TECNOIDEAL PRODUCTS EXPRESS A DEEP UNDERSTANDING OF THE PROCESSES OF PRODUCTION OF DISPOSABLE MEDICAL DEVICES; MACHINERY EXECUTES ALL MAJOR STEPS REQUIRED BY THE ASSEMBLY AND CONTROL OF DISPOSABLES



Source: Management

34

Notice to Recipient - Strictly Confidential

The information contained in this documentation has been prepared by Medica S.p.A. (the "Company") and its consolidated subsidiaries (together, the "Group") for the sole purpose of the presentation made to you concerning the Company. This presentation and the information contained herein are strictly confidential. Disclosure of the information contained herein to anyone outside of your firm is prohibited. This presentation may not be copied, distributed, reproduced or passed on, directly or indirectly, in whole or in part, or disclosed by any recipient, to any other person (other than as required to those within your organization who agree to be bound by these restrictions) or published in whole or in part, for any purpose or under any circumstances. By attending the meeting where this presentation is made, or by reading the following presentation slides, you further agree to be bound by the following limitations, qualifications and restrictions.

This document does not constitute or form part of any offer to sell or issue or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision. The information and opinions contained in this document are provided as at the date of the presentation and are subject to change. Neither the Company nor the Group nor any other person is under any obligation to update or keep current the information contained in this presentation.

To the extent available, the industry, market and competitive position data contained in this presentation come from official or third-party sources. Third-party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company reasonably believes that each of these publications, studies and surveys has been prepared by a reputable source, none of the Company or Intesa Sanpaolo S.p.A. nor CFO SIM (the "Banks") has independently verified the data contained therein. In addition, certain of the industry, market and competitive position data contained in this presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the markets in which the Company or completeness and are subject to change. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this Presentation.

The information contained in this Presentation is preliminary in nature, subject to updating, correction and amendment and does not purport to be comprehensive. None of the Company, the Banks, any of their respective subsidiary undertakings or affiliates, or their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for/or makes any representation or warranty, express or implied, as to the truth, fullness, accuracy or completeness of the information in this Presentation (or whether any information has been omitted from the presentation) or any other information relating to the Group, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this Presentation or its contents or otherwise arising in connection therewith.

Neither this document nor any part or copy of it may be taken or transmitted into the United States or distributed, directly or indirectly, in the United States, as that term is defined in Regulation S under the US Securities Act of 1933, as amended (the "US Securities Act"). Neither this document nor any part or copy of it may be taken or transmitted into Australia, Canada or Japan or to any resident of Japan, or distributed directly or indirectly in Australia, Canada or Japan or to any resident of Japan. Any failure to comply with this restriction may constitute a violation of United States, Australian, Canadian or Japanese securities laws. This document does not constitute an offer of securities to the public in the United Kingdom or in any other jurisdiction. Persons into whose possession this document comes should observe all relevant restrictions.

This Presentation and the information contained herein are not a solicitation of an offer to buy securities or an offer for the sale of securities in the US (within the meaning of Regulation S under the US Securities Act). The ordinary shares of the Company have not been, and will not be, registered under the US Securities Act and may not be offered or sold in the United States except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the US Securities Act or unless registered under the US Securities Act and in compliance with the relevant state securities laws. There will be no public offering of any securities in the United States.

This presentation is not a prospectus for the purposes of applicable laws and regulations and it has not been approved by any authority.

Notice to Recipient - Strictly Confidential

Forward-Looking Statements: This document may include projections and other "forward-looking" statements within the meaning of applicable securities laws. In particular, all statements that address expectations or projections about the future, including statements about operating performance, market position, industry trends, general economic conditions, expected expenditures, cost-savings, synergies and financial results, are forward-looking statements. Consequently, any statements of historical fact are forward-looking statements.

Forward-looking statements are based on assumptions and current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause actual results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Accordingly, actual events or results or actual performance of the Company or the Group may differ significantly, positively or negatively, from those reflected or contemplated in such forward-looking statements made herein. Factors that might cause such differences include, but are not limited to, the risks that business strategy and plans may not receive the level of market acceptance anticipated; disruptions in general economic and business conditions, particularly in geographic areas where business may be concentrated; higher interest rates, higher loan costs or less desirable loan terms, all of which could increase our costs of funding; continued high levels of, or increases in, unemployment and a general slowdown in commercial activity; leverage and ability to refinance existing indebtedness; the ability to achieve improvements in operating efficiency; foreign currency fluctuations; the ability to retain senior management and attract and retain qualified and experienced employees; the ability to retain existing bank partnership or develop new ones.

The Group and all other persons expressly disclaim any duty, undertaking or obligation to update publicly or release any revisions to any of the information, opinions or forward-looking statements contained in this document to reflect any events or circumstances occurring after the date of the presentation of this document. No representation or warranty is made as to the achievement or reasonableness of and no reliance should be placed on such forward-looking statements.

Projections: Any projection or forecast in this document is based on estimates and assumptions, described in this document, about future events and, as a consequence, is subject to significant economic and competitive uncertainty and other contingencies, none of which can be predicted with any certainty and some of which are beyond the Group's control. Each recipient of this document should be aware that these projections do not constitute a forecast or prediction of actual results and there can be no assurance that the projected results will be realized or achieved, and actual results may be higher or lower than those indicated. None of the Company, the Group, the Banks, nor any of their respective security-holders, directors, officers, employees, advisors or affiliates, or any representatives or affiliates, assumes responsibility for the accuracy of the projections presented herein.

Also presented herein are alternative performance indicators that are not recognized by IFRS. Different companies and investors may calculate these non-IFRS measures differently, so making comparisons among companies on this basis should be done very carefully. These non-IFRS measures have limitations as analytical tools, are not measures of performance or financial condition under IFRS and should not be considered in isolation or construed as substitutes for operating profit or net profit as an indicator of our operations in accordance with IFRS.

This presentation is directed and is only distributed to (i) persons that are located outside the United States, (ii) persons that are either (a) in member states of the European Economic Area ("Member States") and are "qualified investors" within the meaning of Article 2, letter e) of the Regulation (EU) 2017/1129 (the "Qualified Investors") or (b) in Italy and are Qualified Investors according to Article 2, letter e) of the Regulation on Intermediaries No. 20307 of February 15, 2018 or (c) in the United Kingdom and are persons who have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or are high net worth companies, unincorporated associations or partnerships or trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) and investment personnel of any of the foregoing (each within the meaning of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and are "qualified investors" as defined in section 86 of the Financial Services and Markets Act 2000, as amended, or other persons to whom it may otherwise be lawfully communicated.

Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions. No liability to any person is accepted by the Company, the Group or the Banks, including in relation to the distribution of this Presentation in any jurisdiction.